Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Has Average Price Target of $30.25 According to Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been given a consensus recommendation of “Hold” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $30.25.

A number of equities research analysts have commented on the company. Cantor Fitzgerald raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, September 1st. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Roth Capital downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a research note on Monday, July 27th. Finally, Maxim Group cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $7.83 on Wednesday. The stock has a market cap of $455.24 million, a PE ratio of -3.20 and a beta of 0.61. Capricor Therapeutics has a 1 year low of $2.96 and a 1 year high of $40.37. The firm has a fifty day moving average price of $7.76 and a 200-day moving average price of $20.32.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). On average, research analysts expect that Capricor Therapeutics will post -1.71 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. KBC Group NV purchased a new position in shares of Capricor Therapeutics in the first quarter worth $44,000. ACT Capital Management LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at $43,000. Quantinno Capital Management LP increased its holdings in Capricor Therapeutics by 16.8% in the 1st quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company’s stock valued at $440,000 after acquiring an additional 2,083 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in Capricor Therapeutics by 13.2% in the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock valued at $1,104,000 after acquiring an additional 4,240 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in Capricor Therapeutics by 41.2% in the 1st quarter. Sei Investments Co. now owns 17,805 shares of the biotechnology company’s stock valued at $541,000 after acquiring an additional 5,195 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions.

Capricor’s lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration.